FLAMMA HONKAI approved by Chinese National Medical Products Administration (NMPA)
Chignolo D’Isola, Bergamo, Italy – November 1, 2021 – Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, proudly announces that Flamma Honkai has passed its final inspection by the Chinese National Medical Products Administration (NMPA) formally known as the Chinese FDA.
This milestone marks Flamma’s ongoing efforts to continue to bring significant value and trust from its customer base.
“The effort by not only the Flamma Honkai team but the entire Flamma team is a testament to our desire to provide the type of quality that is expected at every Flamma site”, said Kenneth Drew, Ph.D., VP Flamma USA. “Many people are understandably worried about working in China. Flamma has long maintained that we have many Italian sites but one happens to be located in China. Our attention to customer needs helps to set us apart from other CDMOs.”
Flamma is looking to expand our footprint within China and will be moving towards another workshop in the Songmudao Chemical Park in the province of Liaoning. While chemical parks located near Beijing & Shanghai are facing heavy environmental scrutiny & random chemical park closures, being located away from these areas as well as being in a special chemical park located outside of the city of Dalian provides a sense of stability and security.
Flamma Honkai can help companies looking to manufacture APIs within China for the Chinese marketplace. Companies can also take advantage of our Italian sites for APIs as well making Flamma unique within the industry.
For further information, please visit the Flamma website at http://www.flammagroup.com.
Contact Flamma
Kenneth Drew, Ph.D., VP Flamma USA
1-617-515-0975
